Table 1.
Clinical Characteristics of the Included Patients
| Tumor no | Case no | Year | Age at diagn | Sex | Diagnosis | Institute | Transformed/De novo | GC/non-GC | Stage | Follow-up time (Mo) | Outcome | Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 1 | 2007 | 86 | M | DLBCL | Karolinska | Transformed | GC | II A | 40 | DnL | R-CHOP, MIME |
| 2 | 2 | 2007 | 51 | F | DLBCL | Karolinska | De novo | Non-GC | IIIB | 76 | relaps x 2, CCR | R-CHOP, SCT, DHAP |
| 3 | 3 | 2007 | 35 | M | DLBCL | Karolinska | De novo | GC | II A | 76 | CCR | R-CHOP |
| 4 | 4 | 2007 | 46 | M | DLBCL | Karolinska | De novo | GC | III B | 1 | DoL | R-MIME |
| 5 | 5 | 2007 | 61 | M | DLBCL | Karolinska | De novo | Non-GC | III B | 18 | relaps, DoL | R-CHOP, MIME SCT |
| 6 | 6 | 2006 | 29 | F | DLBCL | Karolinska | Transformed | GC | IV A | 83 | CCR | R-CHOP, HDT, SCT |
| 7 | 7 | 2006 | 77 | F | DLBCL | Karolinska | De novo | Non-GC | IV A | 84 | CCR | R-CHOP, RT |
| 8 | 8 | 2006 | 68 | M | DLBCL | Karolinska | De novo | Non-GC | IIA | 84 | CCR | na |
| 9 | 9 | 2006 | 5 | M | DLBCL | Karolinska | Relaps | GC | III | 1 | DoL | NHL BFM-90 |
| 10 | 10 | 2005 | 91 | F | DLBCL | Karolinska | De novo | GC | IA | 70 | DnL | WW, surgery |
| 11 | 11 | 2005 | 54 | M | DLBCL | Karolinska | De novo | Non-GC | IA | 91 | CCR | R-CHOP |
| 12 | 12 | 2005 | 34 | M | DLBCL | Karolinska | Transformed | GC | IIIA | 97 | CCR | R-CHOP |
| 13 | 13 | 2005 | 68 | M | DLBCL | Karolinska | De novo | Non-GC | IIA | 12 | DoL | R-CHOP, CHVP |
| 14 | 14 | 2005 | 74 | F | DLBCL | Karolinska | De novo | Non-GC | IIA | 80 | DnL | R-CHOP |
| 15 | 15 | 2005 | 87 | F | DLBCL | Karolinska | De novo | Non-GC | IV | 1 | DoL | na |
| 16 | 16 | 2005 | 70 | F | DLBCL | Karolinska | Transformed | GC | IV | 14 | DoL | R-CHOP, DHAP, MIME, Fludara, Cytosar |
| 17 | 17 | 2004 | 63 | M | DLBCL | Karolinska | Transformed | GC | IIA | 102 | CCR | R-CHOP |
| 18 | 18 | 2004 | 62 | F | DLBCL | Karolinska | De novo | GC | IIA | 4 | DnL | R-CHOP |
| 19 | 19 | 2004 | 51 | M | DLBCL | Karolinska | De novo | Non-GC | IVA | 108 | relaps, CCR | R-CHOP, MIME, HDT, SCT |
| 20 | 20 | 2004 | 56 | M | DLBCL | Karolinska | De novo | Non-GC | IIIA | 110 | CCR | R-CHOP, Cytosar |
| 21 | 21 | 2004 | 74 | F | DLBCL | Karolinska | Transformed | GC | IIIA | 26 | relaps, DoL | R-CHOP, MIME |
| 22 | 22 | 2004 | 63 | M | DLBCL | Karolinska | Transformed | GC | IV | 104 | relaps, DoL | R-CHOP |
| 23 | 23 | 2003 | 63 | F | DLBCL | Karolinska | Transformed | GC | IA | 120 | CCR | R-CHOP |
| 24 | 24 | 2002 | 59 | M | DLBCL | Karolinska | De novo | na | IA | 60 | CNS relaps, DoL | R-CHOP, RT |
| 25 | 25 | 2002 | 63 | M | DLBCL | Karolinska | Transformed | GC | IV | 15 | cutan relaps, DNL | R-CHOP |
| 26 | 26 | 2002 | 71 | F | DLBCL | Karolinska | De novo | Non-GC | IIA | 20 | DoL | R-CHOP |
| 27 | 27 | 2002 | 63 | M | DLBCL | Karolinska | De novo | Non-GC | IIB | 113 | relaps, AML/MDS - DnL | R-CHOP, RT, R-MIME, SCT, |
| 28 | 28 | 2002 | 48 | M | DLBCL | Karolinska | De novo | Non-GC | IIIB | 133 | CCR | R-CHOP |
| 29 | 29 | 2002 | 49 | M | DLBCL | Karolinska | Transformed | GC | IA | 20 | DoL | R-CHOP |
| 30 | 30 | 2002 | 83 | F | DLBCL | Karolinska | De novo | Non-GC | IIA | 5 | DoL | R-CHOP |
| 31 | 31 | 2001 | 67 | F | DLBCL | Karolinska | Transformed | GC | IIA | 38 | DoL | R-CHOP, R-MIME, RT |
| 32 | 32 | 2001 | 13 | F | DLBCL | Karolinska | De novo | Non-GC | IIA | 139 | CCR | NHL BF M 90 |
| 33 | 33 | 2001 | 32 | M | DLBCL | Karolinska | De novo | Non-GC | IA | 140 | CCR | R-CHOP, RT |
| 34 | 34 | 2001 | 83 | M | DLBCL | Karolinska | De novo | Non-GC | IA | 55 | DnL | R-CHOP, splenectomy |
| 35 | 35 | 2001 | 62 | M | DLBCL | Karolinska | Transformed | GC | IVA | 143 | Relaps, CCR | R-CHOP, R-MIME, RT |
| 36 | 36 | 2001 | 60 | F | DLBCL | Karolinska | De novo | GC | IVA | 144 | CCR | R-CHOP |
| 37 | 37 | 2001 | 56 | F | DLBCL | Karolinska | De novo | GC | IA | 150 | relaps, CCR | R-CHOP, DHAP, SCT |
| 38 | 38 | 2000 | 77 | F | DLBCL | Karolinska | De novo | Non-GC | IIA | 37 | relaps,DoL | R-CHOP, MIME, RT, Gemzar |
| 39 | 39 | 2000 | 81 | M | DLBCL | Karolinska | De novo | GC | na | 1 | DoL | no treatment |
| 40 | 40 | 1999 | 77 | F | DLBCL | Karolinska | De novo | Non-GC | IV | 24 | DoL | R-CHOP |
| 41 | 41 | 1999 | 55 | M | DLBCL | Karolinska | Transformed | Non GC | IV | 53 | DoL | R-CHOP |
| 42 | 42 | 2004 | 63 | F | DLBCL | Karolinska | De novo | GC | II | 108 | CCR | R-CHOP |
| 43 | 43:2 | 2007 | 66 | M | DLBCL | Karolinska | Transformed | GC | IVB | 71 | CCR | R-MIME, SCT |
| 44 | 44:1 | 2001 | 31 | M | DLBCL | Karolinska | Transformed | GC | IV | 150 | CCR | R-CHOP, MIME, Cytosar, autoSCT |
| 45 | 44:2 | 2003 | 33 | M | FL III | Karolinska | na | na | IIIA | 0 | CCR | MIME, alloSCT |
| 46 | 45:1 | 2001 | 49 | M | FL I | Karolinska | na | na | IV | 32 | transformed to DLBCL | splenectomy |
| 47 | 45:2 | 2004 | 52 | M | DLBCL | Karolinska | Transformed | GC | IV | 70 | DoL | R-CHOP, autoSCT, BEAM, DHAP, Gemzar |
| 48 | 46:1 | na | 37 | M | FL n.a. | Uppsala | na | na | na | na | na | na |
| 49 | 46:2 | na | na | M | DLBCL | Uppsala | Transformed | GC | na | na | na | na |
| 50 | 47:1 | na | 61 | M | FL II | Uppsala | na | na | na | na | na | na |
| 51 | 47:2 | na | na | M | DLBCL | Uppsala | Transformed | GC | na | na | na | na |
| 52 | 48:1 | na | 33 | F | FL I | Uppsala | na | na | na | na | na | na |
| 53 | 48:2 | 1992 | 33 | F | DLBCL | Uppsala | Transformed | GC | IIIA | 120 | CCR | CHOP, ABMT |
| 54 | 49:1 | 1988 | 71 | M | FL II | Uppsala | na | na | na | 90 | transformed to DLBCL | WW, chlorambucil |
| 55 | 49:2 | 1995 | 78 | M | DLBCL | Uppsala | Transformed | GC | IVB | 7 | DoL | CHOP |
| 56 | 50:1 | 1994 | 69 | F | FL I | Uppsala | na | na | na | 12 | na | na |
| 57 | 50:2 | 1995 | 70 | F | DLBCL | Uppsala | Transformed | GC | IVA | na | na | na |
| 58 | 51:1 | 1985 | 48 | F | FL I | Uppsala | na | na | na | 60 | transformed to DLBCL | na |
| 59 | 51:2 | 1990 | 53 | F | DLBCL | Uppsala | transformed | GC | IVB | 21 | DoL | CHOP |
| 60 | 52:1 | 1970 | 25 | F | FL I | Uppsala | na | na | na | 247 | transformed to DLBCL | RT, Chlorambucil |
| 61 | 53:1 | 1991 | 50 | F | FL I | Uppsala | na | na | na | 48 | transformed to DLBCL | Chlorambucil, CHOP |
| 62 | 53:2 | 1995 | 54 | F | DLBCL | Uppsala | Transformed | GC | IVB | 38 | DoL | MIME |
| 63 | 54:2 | 1994 | 57 | M | DLBCL | Uppsala | Transformed | GC | IVB | 116 | CCR | CT, ABMT |
| 64 | 55.1 | 1997 | 60 | M | FL I | Uppsala | na | na | na | 14 | transformed to DLBCL | Chlorambucil |
| 65 | 55:2 | 1999 | 62 | M | DLBCL | Uppsala | Transformed | GC | IIB | 38 | CCR | CHOP |
| 66 | 56:1 | 1984 | 71 | F | FL I | Uppsala | na | na | na | 9 | transformed to DLBCL | RT |
| 67 | 56:2 | 1985 | 72 | F | DLBCL | Uppsala | Transformed | GC | IIIB | 4 | DoL | COP |
| 68 | 57:1 | na | 60 | F | FL I | Uppsala | na | na | na | 3 | transformed to DLBCL | splenectomy |
| 69 | 57:2 | na | na | F | DLBCL | Uppsala | Transformed | GC | IVA | 132 | DoL | CHOP |
| 70 | 58:1 | 1992 | 51 | F | FL I | Uppsala | na | na | na | 58 | transformed to DLBCL | CHOP, chlorambucil |
| 71 | 58:2 | 1997 | 56 | F | DLBCL | Uppsala | Transformed | GC | IIIA | na | progression | CT |
| 72 | 58:3 | na | na | F | DLBCL | Uppsala | Transformed | GC | na | 61 | DoL | CT |
| 73 | 59:1 | 1992 | 39 | F | FL I | Uppsala | na | na | na | 96 | progression | WW, chlorambucil, CHOP |
| 74 | 59:2 | na | na | F | FL I | Uppsala | na | na | na | na | progression | WW, chlorambucil, CHOP |
| 75 | 59:3 | na | na | F | FL II | Uppsala | na | na | na | na | transformed to DLBCL | WW, chlorambucil, CHOP |
| 76 | 59:4 | 2000 | 47 | F | DLBCL | Uppsala | Transformed | GC | IIB | 40 | DoL | MIME |
| 77 | 60:1 | 1987 | 39 | F | FL II | Uppsala | na | na | na | 148 | progression | WW, chlorambucil |
| 78 | 60:2 | na | na | F | FL II | Uppsala | na | na | na | na | progression | WW, chlorambucil |
| 79 | 60:3 | na | na | F | FL II | Uppsala | na | na | na | na | progression | WW, chlorambucil |
| 80 | 60:4 | na | na | F | FL I | Uppsala | na | na | na | na | transformed to DLBCL | WW, chlorambucil |
| 81 | 60:5 | 1999 | 51 | F | DLBCL | Uppsala | Transformed | GC | IVA | 48 | DoL | CT |
Mo, months; M, male; F, female; na, not available; DnL, death not related to lymphoma; CCR, continous complete remission; DoL, dead of lymphoma; R, retuximab; CHOP, cyclophosphamide, vincristine, adriamycin, and prednisone; MIME, methyl-gag, iphosphamide, methotrexate, and epiposid; SCT, stem cell transplantation; DHAP, dexamethasone, ara-C, platinum; RT, radio therapy; NHL BFM-90, Berlin Frankfurt Munster protocol; WW, wait and watch; BEAM, carmustine, etoposide, cytarabine, melphalan; ABMT, high dose therapy with autologous stem cell rescue; COP, cyclophosphamide, vincristine, and prednisone; CT, different combination of chemotherapy.